Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2022)

Inhibikase Therapeutics (IKT) has 3 years of Current Deferred Revenue data on record, last reported at $23683.0 in Q3 2022.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $23683.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $23683.0, a N/A change, with the full-year FY2020 number at $2.3 million, changed N/A from a year prior.
  • Current Deferred Revenue reached $23683.0 in Q3 2022 per IKT's latest filing, roughly flat from $23684.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for IKT hit a ceiling of $2.3 million in Q4 2020 and a floor of $23683.0 in Q3 2022.
  • A 3-year average of $753415.2 and a median of $142619.0 in 2021 define the central range for Current Deferred Revenue.
  • On a YoY basis, Current Deferred Revenue climbed as much as 83.39% in 2022 and fell as far as 83.39% in 2022.
  • Tracing IKT's Current Deferred Revenue over 3 years: stood at $2.3 million in 2020, then plummeted by 93.87% to $142619.0 in 2021, then crashed by 83.39% to $23683.0 in 2022.
  • Business Quant data shows Current Deferred Revenue for IKT at $23683.0 in Q3 2022, $23684.0 in Q2 2022, and $142619.0 in Q2 2021.